Universe Pharmaceuticals (UPC) Long-Term Deferred Tax (2020 - 2023)
Historic Long-Term Deferred Tax for Universe Pharmaceuticals (UPC) over the last 4 years, with Q3 2023 value amounting to -$948.0 million.
- Universe Pharmaceuticals' Long-Term Deferred Tax fell 7044085.45% to -$948.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$948.0 million, marking a year-over-year decrease of 7044085.45%. This contributed to the annual value of $599078.0 for FY2023, which is 5554.72% down from last year.
- Per Universe Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at -$948.0 million for Q3 2023, which was down 7044085.45% from $830259.0 recorded in Q1 2023.
- Over the past 5 years, Universe Pharmaceuticals' Long-Term Deferred Tax peaked at $186.5 billion during Q3 2020, and registered a low of -$948.0 million during Q3 2023.
- Its 4-year average for Long-Term Deferred Tax is $30.9 billion, with a median of $927979.0 in 2021.
- Its Long-Term Deferred Tax has fluctuated over the past 5 years, first soared by 5490.54% in 2022, then plummeted by 7044085.45% in 2023.
- Over the past 4 years, Universe Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $186.5 billion in 2020, then plummeted by 100.0% to $869997.0 in 2021, then skyrocketed by 54.91% to $1.3 million in 2022, then tumbled by 70440.85% to -$948.0 million in 2023.
- Its Long-Term Deferred Tax was -$948.0 million in Q3 2023, compared to $830259.0 in Q1 2023 and $1.3 million in Q3 2022.